dalteparin has been researched along with Lung Neoplasms in 49 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the study, the effect of dalteparin on pulmonary adenocarcinoma A549 cell line was observed in vitro." | 7.74 | The effect of dalteparin, a kind of low molecular weight heparin, on lung adenocarcinoma A549 cell line in vitro. ( Chen, X; Qu, X; Xiao, W; Zhou, S, 2008) |
| " In the study, the effect of dalteparin on pulmonary adenocarcinoma A549 cell line was observed in vitro." | 3.74 | The effect of dalteparin, a kind of low molecular weight heparin, on lung adenocarcinoma A549 cell line in vitro. ( Chen, X; Qu, X; Xiao, W; Zhou, S, 2008) |
| "The safety outcome was any on-treatment bleeding event." | 3.30 | Rivaroxaban versus nadroparin for thromboprophylaxis following thoracic surgery for lung cancer: A randomized, noninferiority trial. ( Bao, Y; Chen, C; Chen, L; Chen, Q; Jiang, C; Jiang, G; Li, J; Liu, X; She, Y; Shen, L; Xu, L; Yang, Y; Zhao, M, 2023) |
| " There is a lack of consensus in guidelines regarding the timing of administration and the dosage of thromboprophylactic agents." | 2.75 | Randomised high- and low-dose heparin prophylaxis in patients undergoing thoracotomy for benign and malignant disease: effect on thrombo-elastography. ( Attaran, S; Awad, WI; Somov, P, 2010) |
| "11 patients with breast cancer and 10 patients with lung cancer receiving systemic chemotherapy were studied." | 2.70 | Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. ( Israel, VK; Liebman, HA; Presant, CA; Rochanda, L; Waisman, JR; Weitz, IC, 2002) |
| " No adverse events from this dosing were observed during the duration of therapy." | 1.42 | Achievement of therapeutic anti-Xa levels in a proven heparin-resistant patient through the use of nontraditional high-dose enoxaparin. ( Conwall, K; Krajewski, KC; Krajewski, MP; Smith, K, 2015) |
| "Gefitinib is widely used for the treatment of lung cancer in patients with sensitizing epidermal growth factor receptor mutations, but patients tend to develop resistance after an average of 10 months." | 1.42 | Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation. ( Duan, J; Fan, J; Fan, S; Li, X; Pan, Y; Wang, Y; Xiaokaiti, Y; Yang, H; Yuan, L, 2015) |
| "Massive pulmonary embolisms were shown by means of the computerized tomography." | 1.37 | Successful administration of a low dose of calcium nadroparin in patients suffering from pulmonary embolism and brain metastases: a report of two cases. ( Antonelli, G; Colina, P; Ferraù, F; Giamo, V; Parisi, A; Rotondo, S; Sessa, E; Vitale, FV, 2011) |
| "We present a rare case of a thrombus at the aortic arch found 1 month after cisplatin-based chemotherapy in a 50-year-old patient with a diagnosis of small cell lung cancer; there were no symptoms related to the thrombus." | 1.36 | Aortic thrombosis resolved with enoxaparin in a patient treated with cisplatin-based regimen for small cell lung cancer. ( Baek, SK; Chin, SO; Choi, CW; Han, JJ; Hwang, YH; Lee, JJ; Maeng, CH, 2010) |
| " Clexane was also used for thromboembolic complications prophylaxis during performance of operative intervention (in 40 mg daily dosage during 7-12 days)." | 1.33 | [Perspectives for application of heparin derivates in the treatment of patients with pulmonary cancer]. ( Sukhoversha, OA, 2006) |
| "Using the B16 melanoma mouse model of metastasis, subcutaneous (s." | 1.33 | Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. ( Amirkhosravi, A; Francis, JL; Linhardt, R; Mousa, SA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.04) | 18.2507 |
| 2000's | 18 (36.73) | 29.6817 |
| 2010's | 28 (57.14) | 24.3611 |
| 2020's | 2 (4.08) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, M | 1 |
| Bao, Y | 1 |
| Jiang, C | 1 |
| Chen, L | 1 |
| Xu, L | 1 |
| Liu, X | 1 |
| Li, J | 2 |
| Yang, Y | 1 |
| Jiang, G | 1 |
| She, Y | 1 |
| Chen, Q | 1 |
| Shen, L | 1 |
| Chen, C | 1 |
| Wilts, IT | 1 |
| Hutten, BA | 1 |
| Meijers, JCM | 1 |
| Spek, CA | 1 |
| Büller, HR | 1 |
| Kamphuisen, PW | 1 |
| Groen, HJM | 1 |
| van der Heijden, EHFM | 1 |
| Klinkenberg, TJ | 1 |
| Biesma, B | 1 |
| Aerts, J | 1 |
| Verhagen, A | 1 |
| Kloosterziel, C | 1 |
| Pieterman, R | 1 |
| van den Borne, B | 1 |
| Smit, HJM | 1 |
| Hoekstra, O | 1 |
| Schramel, FMNH | 1 |
| van der Noort, V | 1 |
| van Tinteren, H | 1 |
| Smit, EF | 1 |
| Dingemans, AC | 1 |
| Zhong, GX | 1 |
| Gong, Y | 1 |
| Yu, CJ | 1 |
| Wu, SF | 1 |
| Ma, QP | 1 |
| Wang, Y | 2 |
| Ren, J | 1 |
| Zhang, XC | 1 |
| Yang, WH | 1 |
| Zhu, W | 1 |
| Zhuang, X | 1 |
| Qiao, T | 1 |
| Xu, G | 1 |
| Yuan, S | 1 |
| Zhang, Q | 1 |
| Chen, X | 2 |
| Noble, S | 1 |
| Vitale, FV | 1 |
| Rotondo, S | 1 |
| Sessa, E | 1 |
| Antonelli, G | 1 |
| Colina, P | 1 |
| Parisi, A | 1 |
| Giamo, V | 1 |
| Ferraù, F | 1 |
| Colagiovanni, A | 1 |
| Rizzi, A | 1 |
| Buonomo, A | 1 |
| De Pasquale, T | 1 |
| Pecora, V | 1 |
| Sabato, V | 1 |
| Aruanno, A | 1 |
| Pascolini, L | 1 |
| Nucera, E | 1 |
| Schiavino, D | 1 |
| Carmazzi, Y | 1 |
| Iorio, M | 1 |
| Armani, C | 1 |
| Cianchetti, S | 1 |
| Raggi, F | 1 |
| Neri, T | 1 |
| Cordazzo, C | 1 |
| Petrini, S | 1 |
| Vanacore, R | 1 |
| Bogazzi, F | 1 |
| Paggiaro, P | 1 |
| Celi, A | 1 |
| Ludwig, RJ | 1 |
| Alban, S | 1 |
| Bistrian, R | 1 |
| Boehncke, WH | 1 |
| Kaufmann, R | 1 |
| Henschler, R | 1 |
| Gille, J | 1 |
| Züger, M | 1 |
| Demarmels Biasiutti, F | 1 |
| Wuillemin, WA | 1 |
| Furlan, M | 1 |
| Lämmle, B | 1 |
| Lecumberri, R | 1 |
| López Vivanco, G | 1 |
| Font, A | 1 |
| González Billalabeitia, E | 1 |
| Gúrpide, A | 1 |
| Gómez Codina, J | 1 |
| Isla, D | 1 |
| Galán, A | 1 |
| Bover, I | 1 |
| Domine, M | 1 |
| Vicente, V | 1 |
| Rosell, R | 1 |
| Rocha, E | 1 |
| Vignoli, A | 1 |
| Marchetti, M | 1 |
| Russo, L | 1 |
| Cantalino, E | 1 |
| Diani, E | 1 |
| Bonacina, G | 1 |
| Falanga, A | 1 |
| Alturkistani, A | 1 |
| Ghonem, N | 1 |
| Power-Charnitsky, VA | 1 |
| Pino-Figueroa, A | 1 |
| Migliore, MM | 1 |
| Ek, L | 2 |
| Gezelius, E | 2 |
| Bergman, B | 2 |
| Bendahl, PO | 2 |
| Anderson, H | 1 |
| Sundberg, J | 2 |
| Wallberg, M | 1 |
| Falkmer, U | 1 |
| Verma, S | 1 |
| Belting, M | 2 |
| Esme, H | 1 |
| Can, A | 1 |
| Şehitogullari, A | 1 |
| Gonçalves de Oliveira, K | 1 |
| Strandberg, K | 1 |
| Krämer, R | 1 |
| Papageorgiou, C | 1 |
| Vandreden, P | 1 |
| Marret, E | 1 |
| Bonnet, F | 1 |
| Robert, F | 2 |
| Spyropoulos, A | 1 |
| Galea, V | 1 |
| Elalamy, I | 1 |
| Hatmi, M | 1 |
| Gerotziafas, GT | 1 |
| Basu, S | 1 |
| Pantvaidya, G | 1 |
| Malvadkar, S | 1 |
| Miller, RE | 1 |
| Jones, JC | 1 |
| Tometsko, M | 1 |
| Blake, ML | 1 |
| Dougall, WC | 1 |
| Krajewski, KC | 1 |
| Smith, K | 1 |
| Conwall, K | 1 |
| Krajewski, MP | 1 |
| Pan, Y | 1 |
| Li, X | 2 |
| Duan, J | 1 |
| Yuan, L | 1 |
| Fan, S | 1 |
| Fan, J | 1 |
| Xiaokaiti, Y | 1 |
| Yang, H | 1 |
| Rabener, MJ | 1 |
| Howell, C | 1 |
| Mitma, AA | 1 |
| Varghese, JG | 1 |
| Witt, D | 1 |
| Zarich, SW | 1 |
| Lui, JK | 1 |
| McIntosh, LJ | 1 |
| Escobar Valle, J | 1 |
| Stockl, T | 1 |
| Summers, S | 1 |
| Attaran, S | 1 |
| Somov, P | 1 |
| Awad, WI | 1 |
| Chin, SO | 1 |
| Lee, JJ | 1 |
| Hwang, YH | 1 |
| Han, JJ | 1 |
| Maeng, CH | 1 |
| Baek, SK | 1 |
| Choi, CW | 1 |
| Amirkhosravi, A | 3 |
| Mousa, SA | 4 |
| Amaya, M | 2 |
| Meyer, T | 1 |
| Davila, M | 1 |
| Robson, T | 1 |
| Francis, JL | 3 |
| Abu Arab, W | 1 |
| Kotb, R | 1 |
| Sirois, M | 1 |
| Rousseau, E | 1 |
| Busby, E | 1 |
| Marques, MB | 1 |
| Reynolds, RE | 1 |
| Carey, DE | 1 |
| Czerny, M | 1 |
| Fleck, T | 1 |
| Salat, A | 1 |
| Zimpfer, D | 1 |
| Klepetko, W | 1 |
| Wolner, E | 1 |
| Mueller, MR | 1 |
| Sukhoversha, OA | 1 |
| Linhardt, R | 1 |
| Jooste, EH | 1 |
| Chalifoux, T | 1 |
| Broadman, LM | 1 |
| Liu, CY | 1 |
| Yim, BT | 1 |
| Wozniak, AJ | 1 |
| Rui, Y | 1 |
| Wang, D | 1 |
| Hu, D | 1 |
| Huang, L | 1 |
| Xiao, W | 1 |
| Qu, X | 1 |
| Zhou, S | 1 |
| Griffiths, GO | 1 |
| Burns, S | 1 |
| Noble, SI | 1 |
| Macbeth, FR | 1 |
| Cohen, D | 1 |
| Maughan, TS | 1 |
| Weitz, IC | 1 |
| Israel, VK | 1 |
| Waisman, JR | 1 |
| Presant, CA | 1 |
| Rochanda, L | 1 |
| Liebman, HA | 1 |
| Altinbas, M | 1 |
| Coskun, HS | 1 |
| Er, O | 1 |
| Ozkan, M | 1 |
| Eser, B | 1 |
| Unal, A | 1 |
| Cetin, M | 1 |
| Soyuer, S | 1 |
| Moore, A | 1 |
| Lau, E | 1 |
| Yang, C | 1 |
| Mackool, B | 1 |
| Kuter, DJ | 1 |
| Meyer, G | 2 |
| Besse, B | 2 |
| Doubre, H | 1 |
| Charles-Nelson, A | 1 |
| Aquilanti, S | 1 |
| Izadifar, A | 1 |
| Azarian, R | 2 |
| Monnet, I | 2 |
| Lamour, C | 1 |
| Descourt, R | 2 |
| Oliviero, G | 1 |
| Taillade, L | 2 |
| Chouaid, C | 2 |
| Giraud, F | 2 |
| Falcoz, PE | 1 |
| Revel, MP | 1 |
| Westeel, V | 1 |
| Dixmier, A | 1 |
| Tredaniel, J | 1 |
| Dehette, S | 1 |
| Decroisette, C | 1 |
| Prevost, A | 1 |
| Pichon, E | 2 |
| Fabre, E | 1 |
| Soria, JC | 1 |
| Friard, S | 2 |
| Stern, JB | 1 |
| Jabot, L | 1 |
| Dennewald, G | 2 |
| Pavy, G | 1 |
| Petitpretz, P | 1 |
| Tourani, JM | 1 |
| Alifano, M | 2 |
| Chatellier, G | 2 |
| Girard, P | 2 |
| Matikas, A | 1 |
| Vardakis, N | 1 |
| Souglakos, J | 1 |
| Georgoulias, V | 1 |
| Corbi, P | 1 |
| De Luca, K | 1 |
| Taccone, FS | 1 |
| Starc, JM | 1 |
| Sculier, JP | 1 |
| Mohamed, S | 1 |
| Amathieu, R | 1 |
| Tual, L | 1 |
| Fessenmeyer, C | 1 |
| Dhonneur, G | 1 |
| Mellor, P | 1 |
| Harvey, JR | 1 |
| Murphy, KJ | 1 |
| Pye, D | 1 |
| O'Boyle, G | 1 |
| Lennard, TW | 1 |
| Kirby, JA | 1 |
| Ali, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter, Randomized, Open and Sequential Study to Evaluate the Efficacy and Safety of Bemiparin Administration on the Response to Treatment in Patients Diagnosed With Limited Small Cell Lung Cancer[NCT00324558] | Phase 2 | 39 participants (Actual) | Interventional | 2005-06-30 | Terminated (stopped due to Sponsor stopped due to difficulties to recruit 130 patients required by protocol) | ||
| A Randomized Phase III Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer[NCT00717938] | Phase 3 | 390 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| FRAGMATIC - A Randomised Phase III Clinical Trial Investigating the Effect of FRAGMin Added to Standard Therapy In Patients With Lung Cancer[NCT00519805] | Phase 3 | 2,200 participants (Anticipated) | Interventional | 2007-08-31 | Recruiting | ||
| Analysis of Pro-coagulant and Thrombin-generation Markers for the Prediction of Therapeutic Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism: A Pilot Study[NCT01602445] | 700 participants (Anticipated) | Observational | 2012-07-31 | Completed | |||
| Randomized, Phase III-b, Multi-centre, Open-label, Parallel Study of Enoxaparin (Low Molecular Weight Heparin) Given Concomitantly With Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Gastric and Gastro-oesophageal Cancer[NCT00718354] | Phase 3 | 740 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Effect of Low Molecular Weight Heparin on Survival of Stage I,II or IIIA Non Small Cell Lung Cancer. A Multicenter, Open, Randomized Controlled Trial.[NCT00475098] | Phase 3 | 553 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 trials available for dalteparin and Lung Neoplasms
| Article | Year |
|---|---|
Rivaroxaban versus nadroparin for thromboprophylaxis following thoracic surgery for lung cancer: A randomized, noninferiority trial.
Topics: Anticoagulants; Hemorrhage; Humans; Lung Neoplasms; Nadroparin; Rivaroxaban; Thoracic Surgery; Venou | 2023 |
Association between protein C levels and mortality in patients with advanced prostate, lung and pancreatic cancer.
Topics: Aged; Anticoagulants; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female | 2017 |
Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung | 2019 |
Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; | 2013 |
Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Enoxaparin; Female; Hemorrhage | 2018 |
Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN).
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation; Blood Coagu | 2019 |
Randomised high- and low-dose heparin prophylaxis in patients undergoing thoracotomy for benign and malignant disease: effect on thrombo-elastography.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Drug Administratio | 2010 |
Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung | 2003 |
Sealing of the mediastinum with a local hemostyptic agent reduces chest tube duration after complete mediastinal lymph node dissection for stage I and II non-small cell lung carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aprotinin; Carcinoma, Small Cell; Chest Tubes; Dalte | 2004 |
FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer.
Topics: Adult; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Clinical P | 2009 |
Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Anti | 2002 |
A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; | 2004 |
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, | 2018 |
[Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours].
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Protocols; Combined Modality Therapy; Follow-Up Studies; He | 2011 |
35 other studies available for dalteparin and Lung Neoplasms
| Article | Year |
|---|---|
Significantly inhibitory effects of low molecular weight heparin (Fraxiparine) on the motility of lung cancer cells and its related mechanism.
Topics: Actin Cytoskeleton; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Adhesion; Cell Movement; C | 2015 |
Combination of nadroparin with radiotherapy results in powerful synergistic antitumor effects in lung adenocarcinoma A549 cells.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; Basigin; Cell Movement; Cell Prolifer | 2016 |
A step in the right direction, but one size might not fit all.
Topics: Antineoplastic Agents; Fibrinolytic Agents; Humans; Lung Neoplasms; Nadroparin; Pancreatic Neoplasms | 2009 |
Successful administration of a low dose of calcium nadroparin in patients suffering from pulmonary embolism and brain metastases: a report of two cases.
Topics: Anticoagulants; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cerebellar Neoplasms; Dyspnea; Fem | 2011 |
Delayed hypersensitivity to heparin in a patient with cancer: fondaparinux may be safe but needs to be tested.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adrenal Cortex Hormones; Anticoagulants; Breast Neoplasms; Drug | 2010 |
The mechanisms of nadroparin-mediated inhibition of proliferation of two human lung cancer cell lines.
Topics: Adenocarcinoma; Anticoagulants; Apoptosis; Carcinoma, Squamous Cell; cdc25 Phosphatases; Cell Cycle | 2012 |
The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo.
Topics: Animals; Anticoagulants; Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cell Movement; Dose | 2006 |
Subcutaneous low-molecular-weight heparin for treatment of Trousseau's syndrome.
Topics: Aged; Anticoagulants; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Humans; Injections, S | 1997 |
LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells.
Topics: Angiogenesis Inhibitors; Breast Neoplasms; Cell Line, Tumor; Endothelial Cells; Female; Fibroblast G | 2011 |
Inhibition of PAR-1 Receptor Signaling by Enoxaparin Reduces Cell Proliferation and Migration in A549 Cells.
Topics: A549 Cells; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung | 2019 |
Does the use of postoperative low-molecular-weight heparin in patients with lung cancer increase tube drainage?
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Drainage; Enoxaparin; Female; Heparin, Low-Molecular-Weight; H | 2020 |
Lobectomy and postoperative thromboprophylaxis with enoxaparin improve blood hypercoagulability in patients with localized primary lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Anticoagulants; Blood Coagulation; Blood Coagulation T | 2013 |
Excellent response to combined radioiodine and enoxaparin in the setting of tumor venous thrombosis from differentiated thyroid carcinoma involving internal jugular and subclavian veins.
Topics: Adult; Combined Modality Therapy; Enoxaparin; Female; Humans; Iodine Radioisotopes; Jugular Veins; L | 2013 |
RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases.
Topics: Animals; Anticoagulants; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Enoxaparin; Female; Humans; | 2014 |
Achievement of therapeutic anti-Xa levels in a proven heparin-resistant patient through the use of nontraditional high-dose enoxaparin.
Topics: Drug Resistance, Neoplasm; Enoxaparin; Factor Xa Inhibitors; Heparin; Humans; Lung Neoplasms; Male; | 2015 |
Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, | 2015 |
Chest discomfort in a patient with cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chest Pain; Doxorubici | 2015 |
Stroke and a valvular lesion in a patient with stage IV non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Anticoagulants; Cerebellum; Diagnosis, Differential; E | 2016 |
Facial Drooping, Aphasia, and an Incidental Lung Mass in a Nonsmoker.
Topics: Aged; Air Pollutants, Occupational; Anticoagulants; Aphasia; Atrial Flutter; Carcinoma, Squamous Cel | 2017 |
Aortic thrombosis resolved with enoxaparin in a patient treated with cisplatin-based regimen for small cell lung cancer.
Topics: Anticoagulants; Antineoplastic Agents; Aorta; Cisplatin; Enoxaparin; Humans; Lung Neoplasms; Male; M | 2010 |
Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis.
Topics: Animals; Anticoagulants; Antineoplastic Agents; Blood Coagulation; Cell Line, Tumor; Enoxaparin; Hum | 2010 |
Concentration- and time-dependent effects of enoxaparin on human adenocarcinomic epithelial cell line A549 proliferation in vitro.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Prolif | 2011 |
[Perspectives for application of heparin derivates in the treatment of patients with pulmonary cancer].
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Enoxapari | 2006 |
Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
Topics: Animals; Anticoagulants; Antineoplastic Agents; Blood Coagulation; Cell Line, Tumor; Dose-Response R | 2006 |
A perioperative strategy for the placement of a thoracic epidural catheter in a pediatric patient on high-dose enoxaprin.
Topics: Adult; Anesthesia, Epidural; Anesthetics, Intravenous; Anticoagulants; Enoxaparin; Fentanyl; Hematom | 2007 |
Anticoagulation therapy for radiation-induced myelopathy.
Topics: Anticoagulants; Bone Neoplasms; Enoxaparin; Female; Humans; Lung Neoplasms; Middle Aged; Muscular Di | 2001 |
Role of dalteparin sodium on the growth of cancer cells and tumor-associated angiogenesis in A549 human lung cancer cell line and grafted mouse model.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cisplatin; | 2018 |
The effect of dalteparin, a kind of low molecular weight heparin, on lung adenocarcinoma A549 cell line in vitro.
Topics: Adenocarcinoma; Anticoagulants; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell | 2008 |
Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Anticoagulants; Dalteparin; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle | 2007 |
A 52-year-old-male patient with metastatic non-small-cell lung cancer and recurrent venous thromboembolism in unusual sites despite anticoagulation.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Fatal Outcome; Fibrinolytic Agents; Heparin, Low-Mol | 2013 |
Splenic spontaneous rupture (SSR) and hemoperitoneum associated with low molecular weight heparin: a case report.
Topics: Aged; Anticoagulants; Carcinoma, Small Cell; Female; Fibrinolytic Agents; Hemoperitoneum; Heparin, L | 2003 |
Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.
Topics: Animals; Endothelium, Vascular; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Lipoprot | 2003 |
Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Chick Embryo; Chorioallantoic Membrane; Co | 2004 |
[Docetaxel-induced acute pulmonary capillary-leak syndrome mimicking cardiogenic oedema].
Topics: Acute Disease; Anticoagulants; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capillary Leak S | 2007 |
Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Movement; Chemokine CXCL12; Chemokines, CXC; | 2007 |